Natural Product (NP) Details
| General Information of the NP (ID: NP6152) | |||||
|---|---|---|---|---|---|
| Name |
Apocynin
|
||||
| Synonyms |
Acetovanillone; apocynin; 498-02-2; 4'-Hydroxy-3'-methoxyacetophenone; 1-(4-Hydroxy-3-methoxyphenyl)ethanone; Acetoguaiacone; Apocynine; Acetoguaiacon; 4-Acetyl-2-methoxyphenol; Ethanone, 1-(4-hydroxy-3-methoxyphenyl)-; Acetovanilone; Acetovanyllon; 3-Methoxy-4-hydroxyacetophenone; Acetovanillon; 4-HYDROXY-3-METHOXYACETOPHENONE; 4-Hydroxy-3-methoxyphenyl methyl ketone; 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one; Acetophenone, 4'-hydroxy-3'-methoxy-; NSC 209524; UNII-B6J7B9UDTR; EINECS 207-854-5; BRN 0637373; 3-Metoksy-4-hydroksyacetofenon; 2-methoxy-4-acetylphenol; B6J7B9UDTR; CHEBI:2781; MFCD00008747; NSC-209524; Acetovanillone, 98%; 1-(4-hydroxy-3-methoxy-phenyl)-ethanone; WLN: 1VR DQ CO1; 1-acetyl-4-hydroxy-3-methoxybenzene; CCRIS 7285; 3-Metoksy-4-hydroksyacetofenon [Polish]; AI3-15892; 4-Acetylguaiacol; PubChem3315; Vanilloyl methyl ketone; 1-(4-hydroxy-3-methoxy-phenyl)ethanone; ACMC-1AHLR; apocynin (acetovanillone); bmse000584; bmse010031; AURORA KA-3667; Phenol, 4-acetyl-2-methoxy; 4-08-00-01814 (Beilstein Handbook Reference); MLS001304972; SCHEMBL109514; 4-hydroxy3-methoxyacetophenone; 4hydroxy-3-methoxyacetophenone; Acetovanillone, >=98%, FG; CHEMBL346919; DTXSID7060097; TIMTEC-BB SBB008060; 4-hydroxy -3-methoxyacetophenone; NSC2146; Acetovanillone, analytical standard; HMS3651H03; ZINC162515; 3'-Methoxy-4'-hydroxyacetophenone; HY-N0088; NSC-2146; STR03975; AKOS BBS-00003229; ANW-30844; BBL009710; NSC209524; s2425; SBB008060; STL141075; ZINC00162515; AKOS000120562; 4-Hydroxy-3-methoxyphenyl methyl keton; AS03910; CCG-266327; CM10957; CS-5647; DB12618; FS-3673; MCULE-4549346345; 1-(4-hydroxy-3-methoxyphenyl)-ethanone; NCGC00247065-01; 4'-Hydroxy-3'-methoxyacetophenone, 98%; AC-29981; AK-42915; L911; SMR000752909; 1-(4-Hydroxy-3-methoxyphenyl)-1-ethanone; AM20090774; FT-0618638; ST50213415; SW219526-1; A11989; C11380; M-6166; 21432-EP2311824A1; 21432-EP2314295A1; AA-504/20839006; Q414754; Q-200477; ACETOPHENONE,4-HYDROXY,3-METHOXY ACETOVANILLON; F2191-0004; 4 inverted exclamation marka-Hydroxy-3 inverted exclamation marka-methoxyacetophenone; 16522-48-8; I75
Click to Show/Hide
|
||||
| Species Origin | Picrorhiza kurrooa ... | Click to Show/Hide | |||
| Picrorhiza kurrooa | |||||
| Disease | Asthma [ICD-11: CA23] | Phase 1 | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C9H10O3
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=O)C1=CC(=C(C=C1)O)OC
|
||||
| InChI |
1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3
|
||||
| InChIKey |
DFYRUELUNQRZTB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 498-02-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Edaravone | Motor neuron disease | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male Wistar rats weighing 180-210 g were used in this study. | |||||
| Experimental
Result(s) |
AV and ED prevent CP cardiotoxicity by attenuating oxidative stress and tissue injury, and modulating cytoglobin, and PI3K/Akt/mTOR and Keap1/Nrf2 signaling. | |||||
| Captopril + Losartan | Click to Show/Hide the Molecular Data of This Drug | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | A 5/6 nephrectomy mouse model of CDK was used in this study. | |||||
| Experimental
Result(s) |
Apocynin in conjunction with a coadjuvant for modulating blood pressure may be useful for controlling the progression of CRF. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Cyclophosphamide | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GABPA | Molecule Info | |||
| Up-regulation | Expression | GCLC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | KEAP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | SOD3 | Molecule Info | |||
| In-vivo Model | Male Wistar rats weighing 180-210 g were used in this study. | |||||
| Experimental
Result(s) |
Acetovanillone prevents cyclophosphamide-induced acute lung injury by modulating PI3K/Akt/mTOR and Nrf2 signaling in rats. | |||||
